Inventor
MAIER MARTIN A
US42 patents
⚠️ This page may combine multiple inventors who share the name “MAIER MARTIN A”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ALNYLAM PHARMACEUTICALS INC
32 patentsUS10934544B2Mar 2, 2021
Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC15 citations94
US11286486B2Mar 29, 2022
Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
ALNYLAM PHARMACEUTICALS INC8 citations85
US11504391B1Nov 22, 2022
Modified RNA agents with reduced off-target effect
ALNYLAM PHARMACEUTICALS INC18 citations84
US11198872B2Dec 14, 2021
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations84
US11142766B2Oct 12, 2021
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC4 citations84
US11034958B2Jun 15, 2021
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC7 citations84
US10913950B2Feb 9, 2021
TMPRSS6 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC5 citations84
US10995336B2May 4, 2021
Serpina1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC8 citations83
US10683501B2Jun 16, 2020
Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
ALNYLAM PHARMACEUTICALS INC8 citations83
US11873491B2Jan 16, 2024
Complement component C5 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US11492623B2Nov 8, 2022
Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC4 citations73
US11419942B2Aug 23, 2022
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US11408001B1Aug 9, 2022
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations73
US11162098B2Nov 2, 2021
Complement component C5 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US10988768B2Apr 27, 2021
TMPRSS6 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC3 citations73
US10920223B2Feb 16, 2021
Serpina1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US10814007B2Oct 27, 2020
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC3 citations73
US10683504B2Jun 16, 2020
Serpina1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US9970006B2May 15, 2018
Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes
ALNYLAM PHARMACEUTICALS INC4 citations73
US9725718B2Aug 8, 2017
Compositions and methods for inhibition of expression of protein C (PROC) genes
ALNYLAM PHARMACEUTICALS INC3 citations73
US12049628B2Jul 30, 2024
Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
ALNYLAM PHARMACEUTICALS INC1 citations72
US11725209B2Aug 15, 2023
TMPRSS6 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations72
US10829763B2Nov 10, 2020
TMPRSS6 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC4 citations72
US12590305B2Mar 31, 2026
Complement component C5 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations62
US12492401B2Dec 9, 2025
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations62
US12460206B2Nov 4, 2025
PCSK9 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations62
US12338439B2Jun 24, 2025
Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations62
US12173289B2Dec 24, 2024
Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations62
US12071619B2Aug 27, 2024
SERPINA1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations62
US11725207B2Aug 15, 2023
Serpina1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations62
US11118181B2Sep 14, 2021
Compositions and methods for inhibition of expression of protein C (PROC) genes
ALNYLAM PHARMACEUTICALS INC0 citations62
US10273478B2Apr 30, 2019
Compositions and methods for inhibition of expression of protein C (PROC) genes
ALNYLAM PHARMACEUTICALS INC0 citations52
ISIS PHARMACEUTICALS INC
5 patentsUS6878805B2Apr 12, 2005
Peptide-conjugated oligomeric compounds
ISIS PHARMACEUTICALS INC218 citations99
US6207819B1Mar 27, 2001
Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
ISIS PHARMACEUTICALS INC90 citations98
US7713944B2May 11, 2010
Oligomers comprising activated disulfides which bind to plasma proteins and their use for delivery to cells
ISIS PHARMACEUTICALS INC42 citations92
US7038037B2May 2, 2006
Method for sequential support-bound synthesis of conjugated oligomeric compounds
ISIS PHARMACEUTICALS INC4 citations63
US6462184B2Oct 8, 2002
Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
ISIS PHARMACEUTICALS INC2 citations63